Screening of Promising Chemotherapeutic Candidates from Plants against Human Adult T-Cell Leukemia/Lymphoma

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K16403
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47050:Environmental and natural pharmaceutical resources-related
• Research Institution: Fukuoka University
• Principal Investigator: NAKANO Daisuke 福岡大学, 薬学部, 助教 (30509641)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 成人T細胞白血病 / スクリーニング / ステロイド / 強心配糖体

Outline of Final Research Achievements

Several candidate plant extracts were selected from the results of this screening. Among them, we isolated the active components of some plant extracts such as Physalis alkekengi, Withania somnifera and Physalis philadelphica during this study. In addition, we clarified the structure-activity relationship of Asclepias curassavica and Thuja occidentalis, for which we had previously isolated active compounds, and examined the effect of Asclepias curassavica on the cell cycle. As a result, calotropin, a component obtained from Asclepias curassavica, was found to affect the G2/M phase in MT-1 and MT-2 (HTLV-1-infected cell lines).

Free Research Field

天然物化学

Academic Significance and Societal Importance of the Research Achievements

今回得られた結果より、いくつかの化合物群がMT-1・MT-2細胞に対して効果があることがわかった。現在、ツシジノスタットやバレメトスタットなどの低分子化合物の医薬品も認可されてきており、選択肢は広がってきているが、今回の化合物群はこれらの医薬品と構造が大きく違うこともあり、メカニズムなども同じではないのではと考える。よって今回の化合物群についてさらなる研究を進めることで他方面からの治療効果も期待できると考える。